혈우병 치료 시장 규모, 점유율, 성장 분석 : 유형별, 약물 종류별, 치료법별, 환자별, 치료별, 투여 경로별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)

Global Hemophilia Treatment Market size was valued at USD 13.4 billion in 2023 and is poised to grow from USD 14.28 billion in 2024 to USD 23.82 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

The global Hemophilia Treatment Market has experienced remarkable expansion, driven by medical technology advancements, heightened awareness of the disorder, and improved healthcare access. The market offers a diverse range of products, including clotting factor concentrates like recombinant factor VIII and factor IX, essential for treating hemophilia A and B, respectively. These concentrates significantly decrease bleeding risks by replenishing absent clotting factors. Additionally, gene therapy represents a groundbreaking potential cure, aiming to rectify the genetic defects at the disorder's core. Key growth factors include the rising prevalence of hemophilia, increasing healthcare spending, and a shift towards personalized medicine. With the continuous evolution in genetic engineering and biotechnology, the market is poised for innovative treatment solutions to enhance outcomes and seek definitive cures for hemophilia.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemophilia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemophilia Treatment Market Segmental Analysis

Global Hemophilia Treatment Market is segmented by Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use and region. Based on Type, the market is segmented into Hemophilia A and Hemophilia B. Based on Drug Class, the market is segmented into Vasopressin and Coagulation factors. Based on Therapy, the market is segmented into Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Extended half-life products, Desmopressin, Antifibrinolytic agents, Gene therapy products and Others. Based on Patient, the market is segmented into Pediatric and Adult. Based on Treatment, the market is segmented into Prophylaxis and On demand. Based on Route of Administration, the market is segmented into Injectable, Nasal spray and Oral. Based on End-use, the market is segmented into Hospitals, Clinics, Hemophilia treatment centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemophilia Treatment Market

The global Hemophilia Treatment market is primarily driven by continuous technological advancements in the realm of diagnostics and therapies. Leading players in the industry are focused on developing innovative, cutting-edge tools and medications designed to enhance the effectiveness and precision of hemophilia treatment. Furthermore, substantial investments aimed at expanding specialized hemophilia treatment centers (HTCs) worldwide contribute significantly to the positive market outlook. The combination of enhanced technology and the growth of dedicated treatment facilities is expected to propel the market forward, ensuring better patient outcomes and increased accessibility to quality care for individuals living with hemophilia.

Restraints in the Global Hemophilia Treatment Market

The Global Hemophilia Treatment market faces significant restraints due to the stringent regulatory approval processes enforced by health authorities. These rigorous requirements necessitate that manufacturers undergo comprehensive assessments of safety and efficacy, which can be both time-consuming and resource-heavy. As a result, the lengthy approval times can hinder the market entry of innovative treatment options, ultimately stalling growth and limiting patient access to new therapies. This regulatory burden can create barriers for companies seeking to introduce advancements in hemophilia care, thereby impacting the overall development and competitiveness of the market.

Market Trends of the Global Hemophilia Treatment Market

The global hemophilia treatment market is witnessing significant growth driven by an increase in the incidence of genetic disorders and a rising population of hemophiliac patients. Enhanced diagnostic capabilities and growing awareness around preventive treatment options are further propelling market expansion. Major pharmaceutical firms are realizing lucrative opportunities due to heightened diagnosis rates, while regulatory bodies are initiating campaigns to promote early diagnosis and testing for newborns. This awareness boost not only accelerates treatment accessibility but also invigorates research and development efforts, as companies seek innovative solutions amidst a limited therapeutic landscape. Overall, these trends signal a robust growth trajectory for the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Hemophilia Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B

Global Hemophilia Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Vasopressin
• Coagulation factors

Global Hemophilia Treatment Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Recombinant coagulation factor concentrates therapy
• Plasma derived coagulation factor concentrates therapy
• Non-factor replacement therapy
• Extended half-life products
• Desmopressin
• Antifibrinolytic agents
• Gene therapy products
• Others

Global Hemophilia Treatment Market Size by Patient & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult

Global Hemophilia Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Prophylaxis
• On demand

Global Hemophilia Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Injectable
• Nasal spray
• Oral

Global Hemophilia Treatment Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Hemophilia treatment centers
• Others

Global Hemophilia Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • US
  • Canada
• Europe (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOBI (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptevo Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• uniQure N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations